for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Theravance Biopharma Inc

TBPH.OQ

Latest Trade

22.58USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

15.18

 - 

35.48

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
22.58
Open
--
Volume
--
3M AVG Volume
5.25
Today's High
--
Today's Low
--
52 Week High
35.48
52 Week Low
15.18
Shares Out (MIL)
56.64
Market Cap (MIL)
1,278.86
Forward P/E
-5.18
Dividend (Yield %)
--

Next Event

Theravance Biopharma Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Theravance Biopharma Reports Second Quarter 2019 REVENUE Of $26.2 Mln

Theravance Biopharma Reports New Data From Phase 2 Study Of Ampreloxetine

Theravance Biopharma and Mylan Expand YUPELRI Development and Commercialization Agreement to Include China and Adjacent Territories

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Theravance Biopharma Inc

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Industry

Biotechnology & Drugs

Contact Info

UGLAND HOUSE, SOUTH CHURCH STREET

+1.345.6508086000

http://www.theravance.com

Executive Leadership

Rick E. Winningham

Chairman of the Board, Chief Executive Officer

Andrew Hindman

Chief Financial Officer, Senior Vice President

Ann B. Brady

President - Theravance Biopharma Ireland Limited

Bradford J. Shafer

Executive Vice President, General Counsel, Secretary

.. ..

Senior Vice President - Technical Operations

Key Stats

2.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-4.260

2017

-5.300

2018

-3.990

2019(E)

-4.360
Price To Earnings (TTM)
--
Price To Sales (TTM)
21.29
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-62.53
Return on Equity (TTM)
-48.60

Latest News

Mylan and Theravance's COPD treatment gets FDA approval

Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Mylan and Theravance Biopharma's COPD treatment gets FDA approval

Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

BRIEF-Theravance Expects To Report Data From Phase 2A Study In nOH Patients By July End

* THERAVANCE BIOPHARMA TO HOST KEY OPINION LEADER EVENT FOCUSED ON THE UNMET MEDICAL NEED IN THE TREATMENT OF NEUROGENIC ORTHOSTATIC HYPOTENSION

BRIEF-Theravance Biopharma Q4 Revenue $4.5 Million

* THERAVANCE BIOPHARMA, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage:

BRIEF-Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​

* THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA

BRIEF-Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD

* Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD Source text for Eikon: Further company coverage:

BRIEF-Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin

* Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease

BRIEF-Theravance Biopharma posts Q3 loss of $1.27 per share

* Theravance biopharma, inc. Reports third quarter 2017 financial results and provides business update

BRIEF-Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin

* Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting

BRIEF-Theravance Biopharma reports positive new data from multiple studies of VIBATIV at IDWeek 2017

* Theravance Biopharma reports positive new data from multiple studies of VIBATIV (telavancin) at IDWeek 2017

BRIEF-Theravance Biopharma highlights positive results from impact study of Trelegy Ellipta

* Theravance Biopharma highlights positive headline results from impact study of Trelegy Ellipta announced by Glaxosmithkline and Innoviva

BRIEF-Theravance Biopharma highlights approval of trelegy ellipta for treatment of appropriate patients with COPD in the U.S.

* Theravance Biopharma highlights approval of trelegy ellipta (closed triple) as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US

BRIEF-Theravance Biopharma reports Q2 revenue of $3.5 mln

* Reports second quarter 2017 financial results and provides business update

BRIEF-Theravance Biopharma announces positive top-line results from phase 2B study of velusetrag

* Theravance Biopharma announces positive top-line results from phase 2B study of Velusetrag (TD-5108) in patients with gastroparesis

BRIEF-Theravance Biopharma and Mylan announce positive results from 12-month phase 3 safety study of revefenacin

* Theravance Biopharma and Mylan announce positive results from 12-month phase 3 safety study of revefenacin (TD-4208) in patients with chronic obstructive pulmonary disease (COPD)

BRIEF-Theravance Biopharma reports Q1 revenue $3.1 million

* Theravance Biopharma, Inc. reports first quarter 2017 financial results and provides business update

BRIEF-Theravance Biopharma reports positive clinical response rates for patients in TOUR observational patient registry

* Theravance Biopharma reports positive clinical response rates for patients in TOUR™ observational patient registry in several presentations at ECCMID 2017

BRIEF-Theravance Biopharma CEO's compensation for 2016 was $6.3 mln

* Theravance Biopharma Inc - CEO Rick Winningham's total compensation for 2016 was $6.3 million versus $5.5 million in 2015 - sec filing Source text - http://bit.ly/2o1x5M5 Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up